J&J Strikes While the Iron Is Hot, Acquires Laminar

article image

J&J recently acquired Laminar, the maker of a differentiated left atrial appendage occlusion device, a structural heart fix that prevents stroke in patients with atrial fibrillation. It thus executes on its stated goal of upping its mix of high-growth products.

In late November, Johnson & Johnson announced that it acquired Laminar, the developer of a next-generation device for left atrial appendage occlusion (LAAO). J&J paid $400 million up front for the company and will make additional payments upon the execution of clinical and regulatory milestones.

With the Laminar purchase, J&J gains a differentiated LAAO device to compete in a market with an estimated compound annual growth rate of more than 20%. It’s not the strategic’s first LAAO program; J&J gained the WaveCrest LAA closure device when it acquired Coherex in 2015 (and that product is now in a Phase III pivotal trial estimated to be completed in January 2024, according to clinicaltrials.gov). But Laminar, which recently received FDA approval for a pivotal study slated to begin in early 2024, offers advantages in addressing the limitations of earlier devices.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: